Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breas
Go back to Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative BreasMerck & Co. (NYSE: MRK) | Delayed: 131.95 +0.20 (0.15%) | |||||
---|---|---|---|---|---|---|
Previous Close | $131.75 | 52 Week High | $65.46 | |||
Open | $132.00 | 52 Week Low | $47.97 | |||
Day High | $132.28 | P/E | 89.76 | |||
Day Low | $131.08 | EPS | $1.47 | |||
Volume | 10,201,476 |